BNP Paribas Discount Zert REGN 24.../ DE000PL1Y817 /
| 1/24/2025 11:30:20 AM | Chg.-3.200 | Bid12:29:07 PM | Ask12:29:07 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 564.270EUR | -0.56% | 564.270 Bid Size: 53 |
588.950 Ask Size: 53 |
Regeneron Pharmaceut... | - - | 12/24/2026 | Call |
GlobeNewswire
8/26/2024
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire
8/26/2024
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
8/21/2024
Regeneron Provides Update on Biologics License Application for Linvoseltamab
GlobeNewswire
8/7/2024
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire
7/31/2024
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire
7/3/2024
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire
6/28/2024
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire
6/27/2024
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire
6/26/2024
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire
6/16/2024
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire
6/11/2024
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
5/31/2024
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
5/31/2024
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
5/23/2024
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
5/20/2024
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/17/2024
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
5/13/2024
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/8/2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
4/29/2024
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
4/25/2024
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...